Oncology molecular diagnostics market seen reaching $10.13 billion by 2030

The Business Research Company says the oncology molecular diagnostics market will grow from $5.65 billion in 2025 to $10.13 billion by 2030, driven by precision oncology, liquid biopsy and AI-based interpretation. North America held the largest share in 2025 as the report points to stronger demand for personalized cancer care worldwide.

Why it matters: - Oncology molecular diagnostics is becoming more central to how cancer is detected and treated. - The market's growth reflects rising cancer prevalence, wider use of genetic testing and stronger demand for personalized medicine. - Faster, more precise diagnostics can help clinicians match patients to targeted therapies earlier.

What happened: - The Business Research Company published a report on the oncology molecular diagnostics market covering 2026-2035. - The market is projected to grow from $5.65 billion in 2025 to $6.34 billion in 2026. - The report forecasts the market will reach $10.13 billion by 2030. - The report points to a 12.2% CAGR in the near term and a 12.4% CAGR through the forecast period. - North America held the largest share of the global market in 2025. - Western Europe ranked second by market size in 2025.

The details: - Oncology molecular diagnostics uses genetic markers, proteins and other molecular components to diagnose cancer and guide treatment. - Rising cancer incidence, broader adoption of PCR and sequencing, and more funding for oncology research helped drive recent growth. - Expansion of diagnostic services in hospitals and regulatory approvals for molecular tests also supported the market. - Future growth drivers include precision oncology, liquid biopsy technologies, personalized cancer treatments, AI-assisted data interpretation and expansion into emerging markets. - The report highlights companion diagnostics, biomarker-based testing, cancer screening initiatives and earlier cancer detection as key trends. - The report covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa in addition to North America and Western Europe. - The 2026 edition includes market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company offers a free sample of the report and a full report download through its website: Free sample and Full report.

Between the lines: - The report frames oncology molecular diagnostics as part of a broader shift toward individualized cancer care rather than one-size-fits-all treatment. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022. - That jump signals a wider regulatory and clinical push behind precision medicine, which can lift demand for molecular diagnostics.

What's next: - The market's next phase likely hinges on how quickly liquid biopsy, biomarker testing and AI tools move from adoption to routine use. - Growth in emerging markets could broaden access as diagnostic infrastructure expands. - Cancer screening programs and earlier detection efforts may further increase testing volumes. - The Business Research Company is promoting its 2026 report with market dashboards, infographics and updated forecasting tools.